Nevro to Present at Citi's 2022 Virtual Healthcare Conference

Rhea-AI Summary

Nevro Corp. (NYSE: NVRO), a leader in chronic pain solutions, announced that its Chairman, CEO, and President, D. Keith Grossman, will present at Citi's 2022 Virtual Healthcare Conference on February 24, 2022, at 12:30 pm Eastern Time. A webcast will be available on their website. Nevro has developed the innovative 10 kHz Therapy, which has benefited over 80,000 patients globally, significantly impacting chronic pain treatment.

REDWOOD CITY, Calif., Jan. 31, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at Citi's 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 12:30 pm Eastern Time.

A webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com.

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment.  The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 80,000 patients globally.  Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic trunk and limb pain and painful diabetic neuropathy. 

Senza®, Senza II®, and Senza Omnia™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy.  Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.

Senza, Senza II, Senza Omnia, HFX, HXF Coach, HFX Cloud, HFX Connect, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Chief Corp Communications and Investor Relations Officer
650-433-3247  |  julie.dewey@nevro.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-to-present-at-citis-2022-virtual-healthcare-conference-301470487.html

SOURCE Nevro Corp.

FAQ

What is Nevro Corp's role in chronic pain treatment?

Nevro Corp. specializes in medical devices that provide comprehensive solutions for chronic pain, notably through its proprietary 10 kHz Therapy.

When will Nevro present at the Citi 2022 Virtual Healthcare Conference?

Nevro is scheduled to present on February 24, 2022, at 12:30 pm Eastern Time.

Where can I watch the Nevro conference presentation?

The presentation will be available via webcast on Nevro's website in the Investors section.

What is unique about Nevro's spinal cord stimulation systems?

Nevro's Senza, Senza II, and Senza Omnia systems deliver its proprietary 10 kHz Therapy, which is unique in the market.

How many patients have benefited from Nevro's therapy?

Over 80,000 patients worldwide have experienced improvements in chronic pain through Nevro's 10 kHz Therapy.